All News about Obseva Sa
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022
From ObsEva SA
Via GlobeNewswire
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 26, 2022
From ObsEva SA
Via GlobeNewswire
Via Benzinga
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
September 13, 2022
Via Benzinga
Via Benzinga
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
September 01, 2022
Via Benzinga
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.